This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Receptos Licenses Anti-Interleukin-13 Antibody From AbbVie For Phase 2 Development In Orphan Disease

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13) antibody asset from AbbVie (NYSE: ABBV).

The asset, designated RPC4046 by Receptos, has completed a first-in-human Phase I study. Under the agreement, Receptos will conduct a Phase 2 clinical study to demonstrate proof-of-concept in Eosinophilic Esophagitis (EoE), an indication designated as an Orphan Disease by the US FDA. AbbVie holds an exclusive option to enter into a global co-development collaboration for RPC4046 with Receptos following results of the planned Phase 2 study and regulatory discussions with the FDA.

"We are honored that AbbVie has entrusted a promising Phase 2-ready therapeutic candidate to the Receptos development team to pursue proof-of-concept in EoE, an Orphan Disease growing in prevalence for which there are no approved treatment options," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "We believe that AbbVie's exceptional track record in immunology will be a strong asset in this collaboration."

Upon exercise of the co-development option, AbbVie and Receptos would enter into a collaboration agreement in which the parties would equally share costs of the Phase 3 clinical program and future development on a global basis. Receptos would retain a right to co-promote RPC4046 and share equally in profits in the United States. Outside of the US, AbbVie would hold sole commercial rights and Receptos would be eligible for double digit royalties on net sales. Additional indications may be pursued under the collaboration, as the mechanism of action has been shown to have potential in various immunological and allergic disorders.

Should AbbVie decline to exercise its co-development option for RPC4046, Receptos would obtain a worldwide exclusive commercial license to all indications for RPC4046.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs